ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1014

Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes

Sumanth Chandrupatla1 and Jasvinder Singh2, 1University of Alabama at Birmingham, Birmingham, AL, 2Baylor College of Medicine, Birmingham, AL

Meeting: ACR Convergence 2024

Keywords: Disparities, Heart disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Healthcare Disparities in Rheumatology Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: We aimed to assess whether there is a rural-urban disparity in the incidence of myocardial infarction (MI) hospitalization in patients with rheumatoid arthritis (RA).

Methods: We used the 2016-2019 U.S. data that provides a nationally representative data on all hospitalizations in the U.S. Rural/urban residential status was identified using the NIS PL_NCHS variable, with micropolitan or not metropolitan or micropolitan counties being defined as rural. We assessed the multivariable adjusted odds ratios (aOR) to examine the association of rural residence with MI hospitalization with urban residence as the reference category, while adjusting for demographics, payer, income, hospital characteristics, and the Deyo-Charlson Comorbidity Index, a composite validated comorbidity score commonly used to account for the varying effect of 19 common comorbidities.

Results: The crude rate of MI hospitalization for 100,000 area specific RA hospitalizations was significantly higher for rural versus urban Residents, 2,441 versus 1,878 (p< 0.001). In multivariable adjusted models, compared to urban residence, rural-residing residents with RA had almost twice as likely to be hospitalized with MI with an adjusted odds ratio (aOR) of 1.70 (95% CI, 1.58, 1.84, p< 0.001; Table 1). Compared to lowest quartile, the two highest income quartiles were significantly and independently associated with lower odds of MI hospitalization in RA, aOR were 0.92 (95% CI, 0.86 - 0.98) and 0.85 (95% CI, 0.81 - 0.94, p< 0.001; Table 1). Female sex, African American race, elective admission, Medicare payer, government hospital control, rural hospital location, small hospital bed size, were significantly associated with a lower odds of MI hospitalization (Table 1). The adjusted higher odds of MI hospitalizations in RA patients were confirmed in several sensitivity analyses that: (1) excluded elective admission status, aOR 1.53 (1.42 - 1.65, p< 0.001); (2) Including interaction term for rurality and sex, age, and Deyo-Charlson comorbidity index aOR 1.45 (1.07 - 1.98, p=0.02); (3) consisting of individual Deyo-Charlson comorbidities rather than a categorical scale, aOR 1.53 (1.42 - 1.64, p< 0.001).

Conclusion: Our study findings of rural-urban and SES disparities for MI hospitalizations in RA provide policymakers with data and information for action, that could be used for policy decisions to reduce these gaps, to improve outcomes in rural residents that would also improve overall outcomes.

Supporting image 1

Table 1: Multivariable-adjusted predictors of healthcare utilization for people with Rheumatoid Arthritis hospitalized for Myocardial Infarction (2016_2019)


Disclosures: S. Chandrupatla: None; J. Singh: Adaptimmune Therapeutics, 2, Adept Field Solutions, 2, Aebona Pharmaceuticals, 11, Amarin, Viking and Moderna pharmaceuticals, 11, Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Ad, 11, Charlotte's Web Holdings, 11, Clinical Care options, 2, Enzolytics Inc, 11, Fidia, 2, Focus forward, 2, GeoVax Labs, 11, Intuitive Surgical Inc./Philips Electronics North America, 12, food and beverage payments, Jupiter Life Science, 2, MedIQ, 2, Medscape, 2, Medusas, 2, Navigant consulting, 2, Pieris Pharmaceuticals, 11, PK Med, 2, Practice Point communications, 2, Putnam associates, 2, ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals/DINORA, Frictionless Solution, 2, Schipher, 2, Seres Therapeutics, 11, speaker’s bureau of Simply Speaking, 6, Tonix Parmaceuticals, 11, Trio Health, 2, Two Labs Inc, 2, UBM LLC, 2, WebMD, 2, Zimmer Biomet Holdings, 5.

To cite this abstract in AMA style:

Chandrupatla S, Singh J. Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rural-dwelling-patients-with-rheumatoid-arthritis-or-those-with-lower-income-are-more-likely-to-be-admitted-for-myocardial-infarction-in-the-u-s-and-have-worse-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rural-dwelling-patients-with-rheumatoid-arthritis-or-those-with-lower-income-are-more-likely-to-be-admitted-for-myocardial-infarction-in-the-u-s-and-have-worse-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology